• Immunophenotyping helps distinguish B-PLL from similar diseases, one of its key identifiers is the absence in expression of the surface antigens CD10, CD11c, CD25, CD103 and cyclin D1 - an important regulator of cell-cycle progression. (wikipedia.org)
  • B-prolymphocytes are characterized by: Large size - approximately twice the size of a normal small lymphocyte Round or oval-shaped nuclei Single prominent nucleolus Moderately condensed nuclear chromatin High nuclear-cytoplasmic ratio - indicates more abundant cytoplasm This technique is used to study proteins expressed in cells using immunologic markers. (wikipedia.org)
  • Some patients who successfully respond to treatment also undergo stem cell transplantation to consolidate the response. (wikipedia.org)
  • The nuclei are usually round to oval in shape, with occasional patients having cells with a more irregular nuclear outline that is similar to the cerebriform nuclear shape seen in Sézary syndrome. (wikipedia.org)
  • Most patients with T-cell prolymphocytic leukemia require immediate treatment. (wikipedia.org)
  • A small cell variant comprises 20% of all T-PLL cases, and the Sézary cell-like (cerebriform) variant is seen in 5% of cases. (wikipedia.org)
  • TP53 is an important transcriptional activator of genes involved in the regulation of the G1 checkpoint of the cell cycle as well as certain genes responsible for programmed-cell death (apoptosis). (wikipedia.org)